AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Bonesupport Holding

Declaration of Voting Results & Voting Rights Announcements Feb 28, 2018

3016_iss_2018-02-28_899631c2-4b5c-4690-b063-a2a4991a0d63.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Change in number of shares and votes in BONESUPPORT HOLDINGAB (publ)

Lund, Sweden, 18:00 CET 28 February 2018 - During February, the number of shares and votes in BONESUPPORT HOLDING AB(publ) has increased due to the exercise of warrants. Asof 28 February 2018, the number of shares and votes in BONESUPPORT HOLDING AB(publ) amounts to 50,811,866.

For more information contact:

Richard Davies, CEO

Tel: +46 (0) 46 286 53 70

Björn Westberg, CFO

Tel: +46 (0) 46 286 53 60

Email: [email protected]

About BONESUPPORT™

BONESUPPORTis an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT's marketed bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER(BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company's novel and proprietary CERAMENTtechnology platform.

The Company's products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot. BONESUPPORT's total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45 percent. The Company's financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

The Company's research and development is focused on the continuing development and refinement of its CERAMENTtechnology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.

BONESUPPORTis listed on Nasdaq Stockholm and trades under the ticker "BONEX" (ISINcode: SE0009858152). Further information is available at www.bonesupport.com

*CERAMENTG: Not available in the United States, for investigational use only. CERAMENTV: Not available in the United States

BONESUPPORT™ and CERAMENT® are registered trademarks.

The information in the press release is such that BONESUPPORTHOLDINGAB (publ) is required to disclose pursuant to the Swedish Financial Instruments TradingAct. The information was submitted for publication, through the agency of the contact persons set out above, at 18:00 CETon 28 February 2018.

Talk to a Data Expert

Have a question? We'll get back to you promptly.